Source: European Medicines Agency (EU) Revision Year: 2014 Publisher: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340, Beerse, Belgium
Doribax 500 mg powder for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for solution for infusion (powder for infusion). White to slightly yellowish off-white crystalline powder. |
Each vial contains doripenem monohydrate equivalent to 500 mg doripenem.
| Active Ingredient | Description | |
|---|---|---|
| Doripenem |
Doripenem is a synthetic carbapenem antibacterial agent. Doripenem exerts its bactericidal activity by inhibiting bacterial cell wall biosynthesis. Doripenem inactivates multiple essential penicillin-binding proteins (PBPs) resulting in inhibition of cell wall synthesis with subsequent cell death. |
| List of Excipients |
|---|
|
None. |
Clear 20 ml Type I glass vial.
The medicinal product is supplied in cartons containing 10 vials.
Janssen-Cilag International NV, Turnhoutseweg 30, B-2340, Beerse, Belgium
EU/1/08/467/001
Date of first authorisation: 25 July 2008
| Drug | Countries | |
|---|---|---|
| DORIBAX | Estonia, Singapore, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
